MA33802B1 - Dérivés d'éthynyle - Google Patents
Dérivés d'éthynyleInfo
- Publication number
- MA33802B1 MA33802B1 MA34890A MA34890A MA33802B1 MA 33802 B1 MA33802 B1 MA 33802B1 MA 34890 A MA34890 A MA 34890A MA 34890 A MA34890 A MA 34890A MA 33802 B1 MA33802 B1 MA 33802B1
- Authority
- MA
- Morocco
- Prior art keywords
- lower alkyl
- alkoxy
- formula
- hydroxy
- optionally substituted
- Prior art date
Links
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 title 1
- XEHVFKKSDRMODV-UHFFFAOYSA-N ethynyl Chemical class C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Cette invention concerne des dérivés d'éthynyle de formule (i) ou un sel ou sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, un mélange racémique, ou l'énantiomère et/ou l'isomère optique et/ou le stéréoisomère lui correspondant. Dans la formule (i), x est n ou c-r1 ; y est n ou c-r2 ; z est ch ou n; r4 est un substituant aromatique à 6 chaînons contenant 0, 1 ou 2 atomes d'azote, éventuellement substitué par de 1 à 3 groupes, choisis parmi un atome d'halogène, un groupe alkyle inférieur, alcoxy inférieur ou nrr'; r1 est un atome d'hydrogène, un groupe alkyle inférieur, alcoxy inférieur, hydroxy, hydroxyalkyle inférieur, cycloalkyle inférieur ou est un groupe hétérocycloalkyle éventuellement substitué par un hydroxy ou un alcoxy; r2 est un atome d'hydrogène, un groupe cn, alkyle inférieur ou hétérocycloalkyle; r et r' sont indépendamment l'un de l'autre un atome d'hydrogène ou un groupe alkyle inférieur. De manière surprenante, on a maintenant découvert que les composés de formule générale i sont des modulateurs allostériques positifs (pam) du récepteur métabotrope du glutamate de sous-type 5 (mglur5) et qu'ils sont, par conséquent, utiles pour traiter les maladies liées à ce récepteur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179719 | 2009-12-17 | ||
| PCT/EP2010/069593 WO2011073172A1 (fr) | 2009-12-17 | 2010-12-14 | Dérivés d'éthynyle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33802B1 true MA33802B1 (fr) | 2012-12-03 |
Family
ID=43446449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34890A MA33802B1 (fr) | 2009-12-17 | 2012-05-24 | Dérivés d'éthynyle |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8586581B2 (fr) |
| EP (1) | EP2513102B1 (fr) |
| JP (1) | JP5763094B2 (fr) |
| KR (1) | KR101407856B1 (fr) |
| CN (1) | CN102686589B (fr) |
| AR (1) | AR079467A1 (fr) |
| AU (1) | AU2010332987B2 (fr) |
| BR (1) | BR112012014770A2 (fr) |
| CA (1) | CA2780155A1 (fr) |
| CL (1) | CL2012001596A1 (fr) |
| CO (1) | CO6531478A2 (fr) |
| CR (1) | CR20120269A (fr) |
| EC (1) | ECSP12011977A (fr) |
| ES (1) | ES2551582T3 (fr) |
| IL (1) | IL219371A (fr) |
| MA (1) | MA33802B1 (fr) |
| MX (1) | MX2012006789A (fr) |
| MY (1) | MY162998A (fr) |
| NZ (1) | NZ599553A (fr) |
| PE (1) | PE20121443A1 (fr) |
| PH (1) | PH12012500867A1 (fr) |
| RU (1) | RU2553461C2 (fr) |
| SG (1) | SG181779A1 (fr) |
| TW (1) | TWI448465B (fr) |
| UA (1) | UA107002C2 (fr) |
| WO (1) | WO2011073172A1 (fr) |
| ZA (1) | ZA201204429B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2689956T3 (es) * | 2010-11-05 | 2018-11-16 | Oat Agrio Co., Ltd. | Compuesto de etinilfenilamidina o sal del mismo, procedimiento para producir el mismo y fungicida para una utilización agrícola y hortícola |
| KR101554803B1 (ko) | 2011-04-26 | 2015-09-21 | 에프. 호프만-라 로슈 아게 | Mglur5의 양성 알로스테릭 조절체로서 에틴일 유도체 |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| PE20150708A1 (es) * | 2012-09-27 | 2015-05-15 | Hoffmann La Roche | Derivados de ariletinilo |
| EA026941B1 (ru) * | 2012-10-18 | 2017-06-30 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5 |
| MX2015005375A (es) * | 2012-11-07 | 2015-07-21 | Hoffmann La Roche | Compuestos de triazolo. |
| HRP20200638T1 (hr) | 2015-06-03 | 2020-07-10 | F. Hoffmann - La Roche Ag | Derivati etinila |
| ES2733468T3 (es) | 2015-07-15 | 2019-11-29 | Hoffmann La Roche | Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato |
| SI3484889T1 (sl) | 2016-07-18 | 2020-11-30 | F. Hoffmann-La Roche Ag | Derivati etinila |
| WO2026072192A1 (fr) | 2024-09-27 | 2026-04-02 | Alto Neuroscience, Inc. | Traitement efficace de la dépression chez des patients présentant des troubles cognitifs ou des difficultés d'apprentissage et/ou de mémoire avec un modulateur allostérique positif mglur5 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ510743A (en) * | 1998-10-02 | 2003-10-31 | Novartis Ag | mGluR5 antagonists for the treatment of pain and anxiety |
| CO5271680A1 (es) * | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| US6910976B2 (en) | 2001-06-26 | 2005-06-28 | Stx, Llc | Multi-component lacrosse stick head |
| GB0127433D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| TWI292318B (en) * | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0413605D0 (en) | 2004-06-17 | 2004-07-21 | Addex Pharmaceuticals Sa | Novel compounds |
| WO2006048771A1 (fr) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| JP2008542323A (ja) * | 2005-06-01 | 2008-11-27 | ユセベ ファルマ ソシエテ アノニム | 2−オキソ−1−ピロリジン誘導体、その製造方法及びその使用 |
| CA2755268C (fr) | 2005-11-15 | 2013-12-31 | Array Biopharma, Inc. | Inhibiteurs erbb |
| MX2008016523A (es) | 2006-06-30 | 2009-01-19 | Astrazeneca Ab | Derivados de pirimidina utiles en el tratamiento de cancer. |
| EP1972628A1 (fr) | 2007-03-21 | 2008-09-24 | Schwarz Pharma Ag | Indolizines et leurs dérivés aza analogues en tant que composés actifs du SNC |
| CA2685524A1 (fr) * | 2007-04-30 | 2008-11-06 | Abbott Laboratories | Inhibiteurs d'enzyme diacylglycerol o-acyltransferase de type 1 |
| NZ581817A (en) | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
-
2010
- 2010-12-10 US US12/964,785 patent/US8586581B2/en not_active Expired - Fee Related
- 2010-12-14 MY MYPI2012002710A patent/MY162998A/en unknown
- 2010-12-14 RU RU2012128551/04A patent/RU2553461C2/ru not_active IP Right Cessation
- 2010-12-14 PH PH1/2012/500867A patent/PH12012500867A1/en unknown
- 2010-12-14 SG SG2012044814A patent/SG181779A1/en unknown
- 2010-12-14 NZ NZ599553A patent/NZ599553A/en not_active IP Right Cessation
- 2010-12-14 TW TW099143811A patent/TWI448465B/zh not_active IP Right Cessation
- 2010-12-14 CA CA2780155A patent/CA2780155A1/fr not_active Abandoned
- 2010-12-14 PE PE2012000817A patent/PE20121443A1/es not_active Application Discontinuation
- 2010-12-14 AU AU2010332987A patent/AU2010332987B2/en not_active Ceased
- 2010-12-14 WO PCT/EP2010/069593 patent/WO2011073172A1/fr not_active Ceased
- 2010-12-14 UA UAA201207427A patent/UA107002C2/uk unknown
- 2010-12-14 EP EP10790960.8A patent/EP2513102B1/fr not_active Not-in-force
- 2010-12-14 BR BR112012014770A patent/BR112012014770A2/pt not_active Application Discontinuation
- 2010-12-14 ES ES10790960.8T patent/ES2551582T3/es active Active
- 2010-12-14 JP JP2012543676A patent/JP5763094B2/ja not_active Expired - Fee Related
- 2010-12-14 KR KR1020127018589A patent/KR101407856B1/ko not_active Expired - Fee Related
- 2010-12-14 MX MX2012006789A patent/MX2012006789A/es active IP Right Grant
- 2010-12-14 CN CN201080057081.9A patent/CN102686589B/zh not_active Expired - Fee Related
- 2010-12-15 AR ARP100104641A patent/AR079467A1/es unknown
-
2012
- 2012-04-23 IL IL219371A patent/IL219371A/en not_active IP Right Cessation
- 2012-04-25 CO CO12068169A patent/CO6531478A2/es active IP Right Grant
- 2012-05-22 CR CR20120269A patent/CR20120269A/es unknown
- 2012-05-24 MA MA34890A patent/MA33802B1/fr unknown
- 2012-06-14 CL CL2012001596A patent/CL2012001596A1/es unknown
- 2012-06-15 ZA ZA2012/04429A patent/ZA201204429B/en unknown
- 2012-06-15 EC ECSP12011977 patent/ECSP12011977A/es unknown
-
2013
- 2013-10-16 US US14/055,047 patent/US8933094B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012006789A (es) | Derivados de etinilo. | |
| PH12012500690A1 (en) | Positive allosteric modulators (pam) | |
| CA3000761C (fr) | Derive oxa spiro, son procede de preparation, et ses applications dans des medicaments | |
| NZ788543A (en) | Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy | |
| MA42442A (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| AR063454A1 (es) | Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas. | |
| CN103848785A (zh) | 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途 | |
| MA31674B1 (fr) | Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique | |
| MA35113B1 (fr) | 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5 | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| WO2007039781A3 (fr) | Nouveaux composes | |
| EP2864298A1 (fr) | Composés cycloalkyle-éther et leur utilisation en tant qu'inhibiteurs de bace | |
| MA38885B1 (fr) | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) | |
| CA2450274A1 (fr) | Derives de benzoxazepine et leur utilisation comme stimulants du recepteur de l'ampa | |
| FR2854634A1 (fr) | Nouveaux derives de thiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA32019B1 (fr) | Derives d'azetidines, leur preparation et leur application en therapeutique | |
| AR045548A1 (es) | Derivados de imidazol | |
| MA37895A1 (fr) | Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité | |
| KR20250137706A (ko) | Nlrp3 억제제 | |
| JP2024544554A (ja) | ピラゾロ縮合環化合物及びその使用 | |
| TW202333713A (zh) | 一種噠嗪類化合物、其藥物組合物及應用 | |
| EA201000832A1 (ru) | Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции | |
| MA33386B1 (fr) | Derives d'imidazole en tant qu'antagonistes de mglur5 |